India Sets New Date for MEG Anti-Dumping Probe Hearing

India Pharma Outlook Team | Friday, 30 May 2025

  • DGTR reschedules oral hearing in MEG anti-dumping probe to June 16, 2025, following change in Designated Authority.
  • Case initiated on CPMA's petition alleging MEG dumping from Kuwait, Saudi Arabia, and Singapore, harming Indian manufacturers.
  • Virtual hearing to include stakeholders across the supply chain; potential anti-dumping duties may follow based on findings.

The Directorate General of Trade Remedies (DGTR) has rescheduled the oral hearing for its ongoing anti-dumping investigation into imports of mono ethylene glycol (MEG) from Kuwait, Saudi Arabia, and Singapore.

The oral hearing has been rescheduled for 3:00 PM IST on June 16, 2025, and will be conducted virtually, to facilitate stakeholder participation. This change in procedure follows the appointment of Siddharth Mahajan, who replaces Darpan Jain, as stated in a notification from the government on May 19, 2025.

Also read: Strategies for India to Reduce Its API Dependence on China

MEG is an essential input for polyethylene terephthalate (PET) resins widely used in pharmaceutical packaging. The investigation was initiated based on a complaint by the Chemicals and Petrochemicals Association of India (CPMA) on behalf of its member, Reliance Industries, arguing that outdoor MEG imports are being dumped at unfairly low prices that are causing serious harm to domestic producers.

The case is being examined under the Customs Tariff Act, 1975, and the various anti-dumping regulations. The oral hearing will allow the parties to present evidence and respond to each other's claims, and subsequently the Authority will examine all of the submissions received and make preliminary findings that may include the imposition of provisional anti-dumping duties. The investigation reflects India's growing interest in protecting the domestic manufacturing sector, as reiterated through initiatives like “Make in India” and “Atmanirbhar Bharat”.

© 2025 India Pharma Outlook. All Rights Reserved.